SLC7A11 immunotargeted therapies—such as the SLC7A11-targeted DNA vaccination [108], a virus-like particle immunotherapy targeting the SLC7A11 protein [109], and an anti-SLC7A11 viral vaccine based on the bovine herpesvirus 4 vector [110]—also impede the progression of breast cancer by inhibiting SLC7A11. This evidence concerns the gene SLC7A11 and breast carcinoma.